Stock-Based Compensation Plans - Additional Information (Details)										1 Months Ended	3 Months Ended		6 Months Ended	9 Months Ended		12 Months Ended	48 Months Ended
	Sep. 16, 2026 shares	Jun. 29, 2026 USD ($) $ / shares shares	Feb. 17, 2026 shares	Jul. 07, 2025 tranche $ / shares shares	Jun. 04, 2025 shares	Mar. 04, 2024 shares	Jun. 28, 2023 shares	Aug. 01, 2021 shares	Apr. 25, 2021 shares	Jul. 31, 2019 shares	Sep. 30, 2026 USD ($) shares	Sep. 30, 2025 USD ($) $ / shares	Jun. 29, 2026 $ / shares	Sep. 30, 2026 USD ($) $ / shares shares	Sep. 30, 2025 USD ($) $ / shares	Dec. 31, 2025	Dec. 31, 2023 shares	May 22, 2026 shares	May 19, 2026 shares	Apr. 24, 2026 shares	Mar. 13, 2026 shares	Feb. 12, 2026 shares	Jul. 31, 2025 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total | $											$ 13,908,000,000	$ 3,614,000,000		$ 25,156,000,000	$ 7,555,000,000
Expected dividend yield														0.00%
Incremental expense | $											$ 800,000			$ 1,000,000.0
Series A Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options exercisable (in shares)				1,000,000
Options issued (in shares)				8,666,667
Grant-date fair value (in usd per share) | $ / shares												$ 3.260			$ 3.260
Series B Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options exercisable (in shares)			1,000,000	1,000,000
Expiration period (in years)														10 years
Options issued (in shares)				8,666,667
Warrant exercised (in shares)			5,108,700
Exercise of employee stock options (in shares)			1,000,000
Grant-date fair value (in usd per share) | $ / shares		$ 11.62										3.940	$ 11.62		3.940
Series B Warrants | Royalty Purchase Agreement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant exercised (in shares)			2,557,967								5,108,700			5,108,700								5,108,700
January 2024 Pre-Funded Warrants | Tranche 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options exercisable (in shares)				500,000
Options issued (in shares)				4,662,005
Grant-date fair value (in usd per share) | $ / shares												0.130			0.130
January 2024 Pre-Funded Warrants | Tranche 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options exercisable (in shares)				500,000
Options issued (in shares)				4,662,005
Grant-date fair value (in usd per share) | $ / shares												0.130			0.130
SARs liability
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield													0.00%			0.00%
Authorized (in shares)				3,500,000							115,378			115,378									3,500,000
Options exercisable, ending balance (in usd per share) | $ / shares				$ 7.65
Number of tranches | tranche				5
Remaining outstanding shares (in shares)											100,059			100,059
Grant-date fair value (in usd per share) | $ / shares		$ 8.60										$ 4.040	$ 8.60		$ 4.040
SARs liability | Series B Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options issued (in shares)			410,511
Time based Stock Appreciation Rights
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options exercisable (in shares)				500,000
Expiration period (in years)														10 years
Remaining outstanding shares (in shares)											418,722			418,722
Maximum | SARs liability
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term of options (in years)													2 years 8 months 15 days			2 years 4 months 24 days
Minimum | SARs liability
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term of options (in years)													1 month 2 days			1 year
2021 Employee stock purchase plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum annual contributions per employee (as a percent)									15.00%
Purchase price of the stock, at discount from market price at purchase date (as a percent)									85.00%
Shares available for grant (in shares)						120,000			20,000
Additional shares authorized (in shares)						100,000
Shares issued under the ESPP (in shares)								77,858
Total | $											$ 39,000	$ 22,000		$ 71,000	$ 70,000
2019 Omnibus Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for grant (in shares)										150,000
Expected term of options (in years)														5 years 7 months 28 days	5 years 10 months 28 days
Expected dividend yield														0.00%	0.00%
Options granted in period, weighted-average grant date fair value (in usd per share) | $ / shares														$ 11.80	$ 6.70
2019 Omnibus Equity Incentive Plan | Incentive stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)														4 years
2019 Omnibus Equity Incentive Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term of options (in years)														10 years
2019 Omnibus Equity Incentive Plan | Maximum | Non-statutory options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)														4 years
2019 Omnibus Equity Incentive Plan | Minimum | Non-statutory options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)														3 years
2019 Omnibus Equity Incentive Plan, Evergreen Provision
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional shares authorized (in shares)										490,000							440,887
Additional shares authorized (as a percent)										4.00%
Increase in other share (in shares)		6,000,000			700,000	910,000	444,000
SARs Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total | $		$ 1,600,000									1,100,000	$ 1,500,000		$ 5,500,000	$ 1,500,000
Total unrecognized compensation expense | $											$ 2,400,000			$ 2,400,000
Period over which compensation cost will be recognized (in years)														2 years 6 months
2019 Omnibus Equity Incentive Plan And 2026 Inducement Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional shares authorized (in shares)											6,000,000
Total unrecognized compensation expense | $											$ 43,200,000			$ 43,200,000
Period over which compensation cost will be recognized (in years)														3 years 2 months 4 days
2026 Inducement Equity Compensation Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for grant (in shares)																			1,250,000		3,000,000
Additional shares authorized (in shares)	1,300,000
2026 Inducement Equity Compensation Plan | Chief Medical Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for grant (in shares)																				300,000
2026 Inducement Equity Compensation Plan | Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for grant (in shares)																		1,000,000
2026 Inducement Equity Compensation Plan | Options to purchase common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for grant (in shares)											1,233,650			1,233,650